Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer

被引:28
作者
Chuong, Michael [1 ]
Badiyan, Shahed N. [2 ]
Yam, Man [1 ]
Li, Zuofeng [3 ]
Langen, Katja [2 ]
Regine, William [2 ]
Morris, Christopher [3 ]
Snider, James, III [2 ]
Mehta, Minesh [1 ]
Huh, Soon [3 ]
Rutenberg, Michael [3 ]
Nichols, Romaine C. [3 ]
机构
[1] Miami Canc Inst, Baptist Hlth South Florida, Miami, FL USA
[2] Univ Maryland, Med Sch Med, Baltimore, MD 21201 USA
[3] Univ Florida, Proton Therapy Inst, Jacksonville, FL USA
关键词
Pancreas; pancreatic cancer; proton beam therapy; pencil beam scanning (PBS); passive scattering (PS); dosimetry; FULL-DOSE GEMCITABINE; RADIATION-THERAPY; RADIOTHERAPY; IMRT; ESCALATION; TOXICITY; CHEMOTHERAPY; TRIAL; HEAD;
D O I
10.21037/jgo.2018.03.14
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: With an increasing number of proton centers capable of delivering pencil beam scanning (PBS), understanding the dosimetric differences in PBS compared to passively scattered proton therapy (PSPT) for pancreatic cancer is of interest. Methods: Optimized PBS plans were retrospectively generated for 11 patients with locally advanced pancreatic cancer previously treated with PSPT to 59.4 Gy on a prospective trial. The primary tumor was targeted without elective nodal coverage. The same treatment couch, target coverage and normal tissue dose objectives were used for all plans. A Wilcoxon t-test was performed to compare various dosimetric points between the two plans for each patient. Results: All target volume coverage goals were met in all PBS and passive scattering (PS) plans, except for the planning target volume (PTV) coverage goal (V100% > 95%) which was not met in one PS plan (range, 81.8-98.9%). PBS was associated with a lower median relative dose (102.4% vs. 103.8%) to 10% of the PTV (P=0.001). PBS plans had a lower median duodenal V59.4 Gy (37.4% vs. 40.4%; P=0.014), lower small bowel median V59.4 Gy (0.11% vs. 0.37%; P=0.012), lower stomach median V59.4 Gy (0.01% vs. 0.1%; P=0.023), and lower median dose to 0.1 cc of the spinal cord {35.0 vs. 38.7 Gy [ relative biological effectiveness (RBE)]; P=0.001}. Liver dose was higher in PBS plans for median V5 Gy (24.1% vs. 20.2%; P=0.032), V20 Gy (3.2% vs. 2.8%; P=0.010), and V25 Gy (2.6% vs. 2.2%; P=0.019). There was no difference in kidney dose between PBS and PS plans. Conclusions: Proton therapy for locally advanced pancreatic cancer using PBS was not clearly associated with clinically meaningful reductions in normal tissue dose compared to PS. Some statistically significant improvements in PTV coverage were achieved using PBS. PBS may offer improved conformality for the treatment of irregular targets, and further evaluation of PBS and PS incorporating elective nodal irradiation should be considered.
引用
收藏
页码:687 / 693
页数:7
相关论文
共 23 条
[1]   The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer [J].
Baglan, KL ;
Frazier, RC ;
Yan, D ;
Huang, RR ;
Martinez, AA ;
Robertson, JM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (01) :176-183
[2]   A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer [J].
Ben-Josef, Edgar ;
Schipper, Mathew ;
Francis, Isaac R. ;
Hadley, Scott ;
Ten-Haken, Randall ;
Lawrence, Theodore ;
Normolle, Daniel ;
Simeone, Diane M. ;
Sonnenday, Christopher ;
Abrams, Ross ;
Leslie, William ;
Khan, Gazala ;
Zalupski, Mark M. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (05) :1166-1171
[3]   Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - A systematic review [J].
Bittner, Martin-Immanuel ;
Grosu, Anca-Ligia ;
Brunner, Thomas B. .
RADIOTHERAPY AND ONCOLOGY, 2015, 114 (01) :117-121
[4]   Dose escalation with proton or photon radiation treatment for pancreatic cancer [J].
Bouchard, Myriam ;
Amos, Richard A. ;
Briere, Tina M. ;
Beddar, Sam ;
Crane, Christopher H. .
RADIOTHERAPY AND ONCOLOGY, 2009, 92 (02) :238-243
[5]  
Ceha HM, 2000, CANCER-AM CANCER SOC, V89, P2222, DOI 10.1002/1097-0142(20001201)89:11<2222::AID-CNCR10>3.0.CO
[6]  
2-V
[7]   Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: are noncoplanar beam angles necessary? [J].
Chang, D. S. ;
Bartlett, G. K. ;
Das, I. J. ;
Cardenes, H. R. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (09) :720-724
[8]   A comprehensive dosimetric study of pancreatic cancer treatment using three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), volumetric-modulated radiation therapy (VMAT), and passive-scattering and modulated-scanning proton therapy (PT) [J].
Ding, Xuanfeng ;
Dionisi, Francesco ;
Tang, Shikui ;
Ingram, Mark ;
Hung, Chun-Yu ;
Prionas, Evangelos ;
Lichtenwalner, Phil ;
Butterwick, Ian ;
Zhai, Huifang ;
Yin, Lingshu ;
Lin, Haibo ;
Kassaee, Alireza ;
Avery, Stephen .
MEDICAL DOSIMETRY, 2014, 39 (02) :139-145
[9]   Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice [J].
Frank, Steven J. ;
Cox, James D. ;
Gillin, Michael ;
Mohan, Radhe ;
Garden, Adam S. ;
Rosenthal, David I. ;
Gunn, G. Brandon ;
Weber, Randal S. ;
Kies, Merrill S. ;
Lewin, Jan S. ;
Munsell, Mark F. ;
Palmer, Matthew B. ;
Sahoo, Narayan ;
Zhang, Xiaodong ;
Liu, Wei ;
Zhu, X. Ronald .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (04) :846-853
[10]   Spot Scanning Proton Therapy for Malignancies of the Base of Skull: Treatment Planning, Acute Toxicities, and Preliminary Clinical Outcomes [J].
Grosshans, David R. ;
Zhu, X. Ronald ;
Melancon, Adam ;
Allen, Pamela K. ;
Poenisch, Falk ;
Palmer, Matthew ;
McAleer, Mary Frances ;
McGovern, Susan L. ;
Gillin, Michael ;
DeMonte, Franco ;
Chang, Eric L. ;
Brown, Paul D. ;
Mahajan, Anita .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (03) :540-546